Furthermore, a phase 1 clinical study in 2024 demonstrated that anti-BCMA/GPRC5D bispecific CAR T-cell therapy is a promising treatment modality for multiple myeloma, suitable for patients with relapsed or refractory multiple myeloma (R/R MM) (10). Here, TNFRSF17 is linked to AL amyloidosis.